Revelation Biosciences (REVB) Operating Leases (2025 - 2026)
Revelation Biosciences (REVB) posted quarterly Operating Leases of $723771.0 for Q4 2025.
Revelation Biosciences (REVB) Operating Leases (2025 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Operating Leases for 1 consecutive years, with $723771.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases changed N/A year-over-year to $723771.0; the TTM figure through Dec 2025 stood at $723771.0 (changed N/A YoY), while the FY2025 annual figure was $723771.0, changed N/A from the prior year.
- Operating Leases steadied at $723771.0 in Q4 2025 per REVB's latest filing.
- Across five years, Operating Leases topped out at $723771.0 in Q4 2025 and bottomed at $723771.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Revelation Biosciences | 4.08 Mn | -7.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 550,546.00 |
| Dec 31, 2025 | 723,771.00 |